Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research focused on Rituximab and Regimen, with related work in Diffuse large B-cell lymphoma, Lymphoma, Neutropenia. Notable publications include 'Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China', 'Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell...', and 'Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial'.
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma
61 | A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)
48 | NOVEL TRIPLET COMBINATION OF ORELABRUTINIB, LENALIDOMIDE, AND RITUXIMAB AS FRONTLINE THERAPY FOR MANTLE CELL LYMPHOMA: FINAL RESULTS OF POLARIS MULTICENTER PHASE II STUDY
Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial
752 | SAFETY AND EFFICACY OF BRENTUXIMAB VEDOTIN IN CHINESE ADULTS WITH CD30+ PERIPHERAL T‐CELL LYMPHOMA: A SUBGROUP ANALYSIS OF BRAVE STUDY
366 | EVOLVING TREATMENT LANDSCAPE AND OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: A 15‐YEAR MULTICENTER RETROSPECTIVE ANALYSIS FROM CHINA HIGHLIGHTING THE IMPACT OF NOVEL THERAPIES
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study
Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates
Safety and effectiveness of brentuximab vedotin in Chinese adult patients with classical Hodgkin's lymphoma: Results from a multicenter, prospective, observational, real-world study
Effectiveness and safety of polatuzumab vedotin in real-world clinical practice in Chinese patients with diffuse large B-cell lymphoma (POLAREAL): An interim analysis from a prospective, multicenter, observational registry study
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma
Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCD
Time to lymphoma treatment within 24 months in ‘watch and wait’ follicular lymphoma is associated with inferior outcomes: A multicentre analysis
Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)
Comparison of tucidinostat with CHOP-like versus CHOP-like in first-line treatment of peripheral T-cell lymphoma: a single-center real-world study
A novel and selective oral PI3Kα/δ inhibitor, TQ-B3525, in patients with relapsed and/or refractory follicular lymphoma: A phase II, single-arm, open-label study.
Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study
Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study
The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma
Application of circulating tumour DNA in terms of prognosis prediction in Chinese follicular lymphoma patients
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
Update Results of a Phase II Trial of Venetoclax in Combination with Azacitidine and Chidamide in Relapsed/Refractory Acute Myeloid Leukemia
A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses
Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis
ORELABRUTINIB‐LENALIDOMIDE‐RITUXIMAB (OLR) IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (MCL): A PROSPECTIVE, MULTICENTER, SINGLE‐ARM PHASE 2 POLARIS STUDY IN CHINA
[Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A national multicenter survey research].